Michael Robinson

Title: Innovations by Inventor Michael Robinson in Hepatitis B Treatment

Introduction

Michael Robinson, a prominent inventor based in San Francisco, CA, has made significant contributions to the field of virology, particularly in the treatment of hepatitis B virus (HBV). With a total of five patents to his name, Robinson's work emphasizes the importance of RNA interference in the modulation of viral gene expression.

Latest Patents

One of Robinson's latest patents focuses on "RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)." This invention presents compounds, compositions, and methods designed to study, diagnose, and treat conditions that are affected by HBV gene expression. Through this patent, Robinson explores double-stranded nucleic acid molecules, such as short interfering RNA (siRNA), micro-RNA (miRNA), and various small nucleic acid molecules capable of mediating RNA interference (RNAi) to inhibit HBV gene expression.

Career Highlights

Michael Robinson is associated with Sirna Therapeutics, Inc., a company dedicated to advancing RNA interference technology for therapeutic applications. His innovative work, especially in developing treatments for HBV, showcases his commitment to addressing significant health challenges. His expertise and inventions have played a crucial role in expanding the therapeutic options available for combating viral infections.

Collaborations

Throughout his career, Robinson has collaborated with esteemed colleagues, including Duncan F. Brown and Steven Bartz. These collaborative efforts at Sirna Therapeutics have enriched his research endeavors, bringing together diverse expertise to enhance the understanding and treatment of HBV.

Conclusion

Michael Robinson stands out as a key inventor in the realm of hepatitis B research. His patents demonstrate a blend of scientific innovation and practical application, aimed at mitigating the effects of viral infections through advanced RNA interference techniques. As the fight against diseases like hepatitis B continues, Robinson's contributions will remain vital in shaping future therapeutic strategies.